Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion type Assertion NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_head.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion wasGeneratedBy ECO_0000203 NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_provenance.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion wasDerivedFrom befree-20150227 NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_provenance.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion SIO_000772 23427296 NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_provenance.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion evidence source_evidence_literature NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_provenance.
- NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_assertion description "[CD74 is a suitable target for ADCs in some solid tumor xenografts, with efficacy largely influenced by uniformity of CD74 expression and with SN-38 conjugates providing the best therapeutic responses; SN-38 conjugates were preferable in solid cancers, whereas doxorubicin ADC was better in lymphoma tested.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP297928.RAku9F-5PFpd2CFsrv7p7mY2mA6UhfDiIzlHyVB9BKe-U130_provenance.